دورية أكاديمية
أعرض في EDS

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes.

التفاصيل البيبلوغرافية
العنوان: Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes.
المؤلفون: LoCastro M; School of Medicine and Dentistry, University of Rochester, Rochester, NY., Baran AM; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Liesveld JL; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Huselton E; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Becker MW; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., O'Dwyer KM; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Aljitawi OS; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Baumgart M; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Snyder E; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Kluger B; Department of Neurology; and.; Division of Palliative Care, Department of Medicine, University of Rochester Medical Center, Rochester, NY., Loh KP; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute., Mendler JH; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute.
المصدر: Blood advances [Blood Adv] 2021 Dec 28; Vol. 5 (24), pp. 5554-5564.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/therapy , Myelodysplastic Syndromes*/therapy, Adult ; Death ; Hospital Mortality ; Humans ; Retrospective Studies
مستخلص: Patients with acute myeloid leukemia (AML) or a myelodysplastic syndrome (MDS) experience high rates of hospitalization, intensive care unit (ICU) admission, and in-hospital death at the end of life. Early goals-of-care (GOC) discussions may reduce the intensity of end-of-life (EOL) care. Portable Medical Order forms, known as Medical Orders for Life-Sustaining Treatment (MOLST) forms in New York state, assist patients in translating GOC discussions into specific medical orders that communicate their wishes during a medical emergency. To determine whether the timing of completion of a MOLST form is associated with EOL care in patients with AML or MDS, we conducted a retrospective study of 358 adult patients with AML or MDS treated at a single academic center and its affiliated sites, who died during a 5-year period. One-third of patients completed at least 1 MOLST form >30 days before death. Compared with patients who completed a MOLST form within 30 days of death or never, those who completed a MOLST form >30 days before death were less likely to receive transfusion (adjusted odds ratio [AOR], 0.39; P < .01), chemotherapy (AOR, 0.24; P < .01), or life-sustaining treatments (AOR, 0.21; P < .01) or to be admitted to the ICU (AOR, 0.21; P < .01) at EOL. They were also more likely to use hospice services (AOR, 2.72; P < .01). Earlier MOLST form completion was associated with lower intensity of care near EOL in patients with MDS or AML.
(© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Leukemia. 2004 Apr;18(4):809-16. (PMID: 14762444)
J Natl Compr Canc Netw. 2017 Aug;15(8):989-997. (PMID: 28784860)
JAMA Intern Med. 2015 Apr;175(4):549-56. (PMID: 25642797)
Cancer. 2020 Feb 1;126(3):515-522. (PMID: 31593321)
J Oncol Pract. 2014 Nov;10(6):e396-403. (PMID: 25294393)
Arch Intern Med. 2012 Aug 13;172(15):1133-42. (PMID: 22777380)
JAMA. 2004 Dec 8;292(22):2765-70. (PMID: 15585737)
Cancer. 2016 Apr 15;122(8):1209-15. (PMID: 26914833)
J Oncol Pract. 2017 Oct;13(10):e881-e888. (PMID: 28727486)
Am J Hosp Palliat Care. 2019 Jul;36(7):564-570. (PMID: 30700127)
BMC Cancer. 2019 Feb 8;19(1):130. (PMID: 30736754)
J Clin Oncol. 2012 Dec 10;30(35):4387-95. (PMID: 23150700)
J Natl Compr Canc Netw. 2018 Sep;16(9):1055-1064. (PMID: 30181417)
J Clin Oncol. 2017 Oct 20;35(30):3417-3424. (PMID: 28783450)
Gynecol Oncol. 2013 Jul;130(1):152-5. (PMID: 23542684)
J Clin Oncol. 2017 Jan;35(1):96-112. (PMID: 28034065)
Cancer. 2014 Jun 1;120(11):1743-9. (PMID: 24967463)
Cancer. 2014 May 15;120(10):1572-8. (PMID: 24549743)
Cancer. 2017 Sep 1;123(17):3377-3384. (PMID: 28542833)
Cancer. 2020 Mar 15;126(6):1306-1314. (PMID: 31809566)
Am J Hosp Palliat Care. 2020 Sep;37(9):692-700. (PMID: 31867978)
Cancer. 2015 Aug 15;121(16):2840-8. (PMID: 25926135)
J Pain Symptom Manage. 2014 Nov;48(5):839-51. (PMID: 24703943)
J Pain Symptom Manage. 2020 Apr;59(4):894-915.e14. (PMID: 31639495)
J Palliat Care. 2018 Jul;33(3):125-142. (PMID: 29607704)
معلومات مُعتمدة: K02 AG062745 United States AG NIA NIH HHS; K99 CA237744 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20210915 Date Completed: 20220107 Latest Revision: 20220416
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8714721
DOI: 10.1182/bloodadvances.2021004775
PMID: 34525170
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2021004775